<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">36008115</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2022</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle><b>Somatic symptom disorder in patients with post-COVID-19 neurological symptoms: a preliminary report from the somatic study (Somatic Symptom Disorder Triggered by COVID-19</b>).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jnnp-2021-327899</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-327899</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the diagnosis of somatic symptom disorder (SSD) in patients with unexplained neurological symptoms occurring after SARS-CoV-2 infection, also referred to as long COVID.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Single-centre observational study.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adult patients experiencing unexplained long-lasting neurological symptoms after mild COVID. Of the 58 consecutive patients referred in our centre, 50 were included.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Patients were contacted for a standardised psychometric evaluation by phone, followed by a self-survey.</AbstractText><AbstractText Label="MAIN OUTCOME" NlmCategory="RESULTS">Positive diagnosis of SSD according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although the patients did not meet the DSM-5 criteria for a functional neurological symptom disorder specifically, SSD diagnosis based on DSM-5 criteria was positive in 32 (64%) patients. In the remaining 18 patients, SSD was considered possible given the high score on diagnostic scales. Physical examination were normal for all. Brain MRI showed unspecific minor white matter hyperintensities in 8/46 patients. Neuropsychological assessment showed exclusively mild impairment of attention in 14 out of 15 tested patients, in discrepancy with their major subjective complaint. Forty-five (90%) patients met criteria for Chronic Fatigue Syndrome. Seventeen (32%) patients were screened positive for mood-anxiety disorders, 19 (38%) had a history of prior SSD and 27 (54%) reported past trauma. Additional self-survey highlighted post-traumatic stress disorder in 12/43 (28%), high levels of alexithymia traits and perfectionism. Long-lasting symptoms had a major impact with a high rate of insomnia (29/43, 67%), psychiatric follow-up (28/50, 56%) and work or pay loss (25/50, 50%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A majority of patients with unexplained long-lasting neurological symptoms after mild COVID met diagnostic criteria for SSD and may require specific management.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NCT04889313.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kachaner</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8992-7539</Identifier><AffiliationInfo><Affiliation>Internal Medicine, Universit&#xe9; Paris Cit&#xe9;, Paris, France alexandra.kachaner@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemogne</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Psychiatry, Universit&#xe9; Paris Cit&#xe9;, INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, Service de Psychiatrie de l'adulte, AP-HP, H&#xf4;pital H&#xf4;tel-Dieu, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dave</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology, Centre Hospitalier de Saint Denis, Saint Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranque</LastName><ForeName>Brigitte</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Internal Medicine, Internal Medicine Department, AP-HP, H&#xf4;pital Europ&#xe9;en Georges Pompidou, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris Cit&#xe9;, Inserm UMR S970, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Broucker</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurology, Centre Hospitalier de Saint Denis, Saint Denis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meppiel</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology, Centre Hospitalier de Saint Denis, Saint Denis, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04889313</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">functional neurological disorder</Keyword><Keyword MajorTopicYN="N">somatisation disorder</Keyword></KeywordList><CoiStatement>Competing interests: CL reports personal fees and non-financial support from Janssen-Cilag, Lundbeck, Otsuka Pharmaceutical and Boehringer Ingelheim, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>25</Day><Hour>21</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36008115</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-327899</ArticleId><ArticleId IdType="pii">jnnp-2021-327899</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>